Eli Lilly And Co (NYSE:LLY) on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders. The transaction includes STC-004, a Phase 2 ready Nav1.8…
Continue reading...